Last C$0.54 CAD
Change Today -0.01 / -1.82%
Volume 103.7K
ONC On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 12:47 PM 12/24/14 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONC) Snapshot

Open
C$0.56
Previous Close
C$0.55
Day High
C$0.58
Day Low
C$0.54
52 Week High
03/21/14 - C$2.31
52 Week Low
10/10/14 - C$0.45
Market Cap
48.4M
Average Volume 10 Days
81.1K
EPS TTM
C$-0.23
Shares Outstanding
89.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONC)

oncolytics biotech inc (ONC) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONC) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONC) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

Founded in 1998

oncolytics biotech inc (ONC) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $271.2K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONC) Key Developments

Oncolytics Biotech Inc. Announces Filing for Orphan Drug Designation with the U.S. FDA for Pancreatic and Ovarian Cancers

Oncolytics Biotech Inc. announced that it has submitted applications for Orphan Drug Designation to the U.S. Food and Drug Administration for REOLYSIN® for the treatment of pancreatic and ovarian cancers. The FDA grants Orphan Drug Designation status to products that treat rare diseases, providing incentives to sponsors developing drugs or biologics. The FDA defines rare diseases as those affecting fewer than 200,000 people in the United States at any given time. Orphan Drug Designation provides the sponsor certain benefits and incentives, including a period of marketing exclusivity if regulatory approval is ultimately received for the designated indication, potential tax credits for certain activities, eligibility for orphan drug grants, and the waiver of certain administrative fees.

Oncolytics Biotech Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 08:35 AM

Oncolytics Biotech Inc. Presents at Stifel Healthcare Conference 2014, Nov-19-2014 08:35 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Bradley G. Thompson, Executive Chairman, Chief Executive Officer and President.

Oncolytics Biotech Inc. Announces Consolidated Earnings Results for Third Quarter and Nine Months Ended Sept. 30, 2014

Oncolytics Biotech Inc. announced consolidated earnings results for third quarter and nine months ended Sept. 30, 2014. For the quarter, the company reported operating loss of $4,677,213, loss before income taxes of $4,637,276, net loss of $4,636,608, net comprehensive loss of $4,536,147 or $0.05 per basic and diluted share cash used in operating activities of $4,415,215, acquisition of property and equipment of $113,782 compared to the operating loss of $6,224,129, loss before income taxes of $6,113,650, net loss of $6,113,650, net comprehensive loss of $6,147,163 or $0.07 per basic and diluted share cash used in operating activities of $6,509,872, acquisition of property and equipment of $103,512 for the same quarter a year ago. For the year to date, the company reported operating loss of $15,011,671, loss before income taxes of $14,833,494, net loss of $14,840,222, net comprehensive loss of $14,731,780 or $0.17 per basic and diluted share cash used in operating activities of $16,359,528, acquisition of property and equipment of $131,001 compared to the operating loss of $18,030,973, loss before income taxes of $17,740,167, net loss of $17,740,167, net comprehensive loss of $17,666,041 or $0.21 per basic and diluted share cash used in operating activities of $20,029,692, acquisition of property and equipment of $250,814 for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONC:CN C$0.54 CAD -0.01

ONC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONC.
View Industry Companies
 

Industry Analysis

ONC

Industry Average

Valuation ONC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.